Tizanidine Hydrochloride Capsule
Product Images NDC 72789-506

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 72789-506). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

72789506 Label (72789506)

72789506 Label (72789506)
This text is a detailed description of a medication containing tizanidine hydrochloride. Each capsule contains 2.29mg of tizanidine hydrochloride, which is equivalent to 2 mg of tizanidine base. The medication should be stored at 25°C (77°F) and excursions are permitted to 15° - 30°C (59° - 86°F). It should be dispensed in containers with child-resistant closures and kept out of reach of children. The prescribing information can be found in the package insert and additional information can be viewed or printed using the provided NDLC code. Lastly, the medication is manufactured by Rubicon Research Private Limited in India and inquiries can be directed to PD-Rx Pharmaceuticals, Inc.*
FDA Label Image

Figure 1 (Tizanidine Hydrochloride Capsules Figure 1)

Figure 1 (Tizanidine Hydrochloride Capsules Figure 1)
FDA Label Image

Figure 2 (Tizanidine Hydrochloride Capsules Figure 2)

Figure 2 (Tizanidine Hydrochloride Capsules Figure 2)
This text seems to mention the dosage of tizanidine (16 mg and 8 mg) and references an improvement in Ashworth Score over time post-dose. It likely relates to a study or report on the effects of tizanidine on muscle spasticity.*
FDA Label Image

Figure 3 (Tizanidine Hydrochloride Capsules Figure 3)

Figure 3 (Tizanidine Hydrochloride Capsules Figure 3)
This passage discusses Tizanidine, a medication that was tested at a mean dose of 28.8 mg in comparison to a placebo. It mentions improvements in the Ashworth Score over the course of the study, with endpoints at the end of titration, end of maintenance, and at the last observation carried forward.*
FDA Label Image

Chemical Structural Formula (Tizanidine Hydrochloride Capsules Structure)

Chemical Structural Formula (Tizanidine Hydrochloride Capsules Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.